Transcend Therapeutics
Edit info- Founded: 2021
- Location: New York, NY
- Employee range: 1 - 10
- Clinical stage: Clin2
- Therapy area: mental illness
- Drug types: PSY
- Lead product: TSND-201
- Funding: $40M A Feb 2023
- Investors: Alpha Wave Global, Integrated Investment Partners
transcendtherapeutics.com linkedin.com job board
Business:
Psychedelics
Drug notes:
Also Clin1 depression, Clin1 CNS disorders; undisclosed programs RD/Clin0 undisclosed
About:
Transcend Therapeutics is discovering and developing psychedelic medicines for neuropsychiatry. The largest cause of disability worldwide is now neuropsychiatric illnesses with 1 billion people currently suffering; however there is little investment and innovation in developing new treatments. Transcend aims to rectify this problem by identifying psychedelics with clinical and nonclinical safety profiles and prioritizing those with therapeutic effect. Patient access enables Transcend to then verify treatments and identify those with shorter treatment durations, minimal patient inebriation and fewer undesirable effects compared to traditional psychedelics. Transcend’s lead product has demonstrated >85% response rates in patients with depression and PTSD.
Jobs:
News:
This week the Transcend team participated in the American Society for Clinical Psychopharmacology 2024 Annual Meeting. We were pleased to present three posters on TSND-201 (methylone), which demonstra
linkedin
May 27, 2024
Science/business updates
external-link
PTSD treatment is on the cusp of a paradigm shift. This biotech hopes to Transcend the competition - Fierce Biotech
googlenews
Dec 5, 2023
Science/business updates
external-link
Exclusive: AlleyCorp raises a $250 million fund, taking on external investors for the first time
linkedin
Dec 27, 2024
Funding-related
external-link
Psychoactive drug methylone tested as new PSTD treatment in London trial - BioPharma-Reporter.com
googlenews
Oct 19, 2023
Science/business updates
external-link
Psychoactive drug methylone to be tested as PTSD treatment - Evening Standard
googlenews
Oct 17, 2023
Science/business updates
external-link
Transcend Therapeutics and Yale awarded U.S. Department of Defense grant to study methylone for PTSD - PR Newswire
googlenews
Sep 21, 2023
Funding-related
external-link
Wall Street Backs New Class of Psychedelic Drugs - The Wall Street Journal
googlenews
Feb 23, 2023
Science/business updates
external-link
Transcend Therapeutics, a mental health-focused biotechnology company, announces Series A funding round of $40 million led by Alpha Wave Global and Integrated Investment Partners - PR Newswire
googlenews
Feb 23, 2023
Funding-related
external-link
Transcend Therapeutics announces publication of new preclinical data demonstrating TSND-201 (methylone) is a rapid-acting neuroplastogen with fewer off-target effects than MDMA - Transc
linkedin
Dec 27, 2024
Science/business updates
external-link
We are thrilled to welcome Robert Barsic to the Transcend Therapeutics team as a Sr Clinical Trial Associate!
Bobby joins us from Mount Sinai Health System, where he excelled as a Clinical Research C
linkedin
Dec 27, 2024
New hires
external-link
We are thrilled to welcome Luke Frering to the Transcend Therapeutics team as our new Clinical Trial Manager!
Luke joins us from Relmada Therapeutics, where he excelled as a Clinical Trial Manager.
linkedin
Apr 27, 2024
New hires
external-link
A revival in neuro therapeutics - FiercePharma
googlenews
Oct 11, 2024
Science/business updates
external-link
Psychoactive Therapies Are Coming Back– With Millions In Funding Behind Them - Forbes
googlenews
Feb 24, 2023
Funding-related
external-link
We are thrilled to welcome Lily Eaker to the Transcend Therapeutics team as our new Senior Clinical Trial Associate!
Lily joins us from Clario, where she was a Project Manager. She led the cardiac sa
linkedin
Jun 27, 2024
New hires
external-link
Pα+ Psychedelic Bulletin #151: Psilocybin for BDII, ACNP Readouts, Methylone for PTSD, and More Psychedelic Drug Dev. News - Psychedelic Alpha
googlenews
Dec 14, 2023
Science/business updates
external-link
Transcend Therapeutics Presents New Data from the Open-Label Portion of the IMPACT-1 Study and Further Data Supporting the Neuroplasticity Mechanism of TSND-201 - Transcend Therapeutics
linkedin
Dec 27, 2024
Science/business updates
external-link
New York tech investor and serial entrepreneur Kevin Ryan explains when to sell your company - TechCrunch
googlenews
Oct 5, 2024
Science/business updates
external-link
© 2025 Work In Biotech LLC
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com